Estimated effects on people, organizations, and industries in bills this legislator sponsored, cosponsored, or voted on. Includes bills they voted against.
These are assessments of legislative text, not measurements of realized outcomes or the legislator’s intent.
Loading policy effects…
This selection could not be loaded. Your current view is still available.
Potential burden on Active pharmaceutical ingredient manufacturers
More compliance requirements
Summary unavailable
2. Require drug labels to include original manufacturer and supply chain information Section 503 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353) is amended by adding at the end the following — (i)Original Manufacturer and Supply Chain Information(1)In generalNo person shall introduce or deliver for introduction into interstate commerce any drug—(A)if it is an active pharmaceutical ing…
Potential burden on Active pharmaceutical ingredient manufacturers
More compliance requirements
Adds or tightens a compliance mandate, definition change, delegation of rulemaking provision: 2. Require drug labeling to include original manufacturer and supply chain information Section 502(b) of the Federal Food,... In practical terms, health care providers and patients face compliance burden up (negative); Federal implementing agencies face compliance burden up (negative).
Potential benefits are effects assessed as favorable to the named group. Potential burdens impose costs, restrictions, risks, or lost opportunities on that group.
Mixed effects contain countervailing effects on the same group. Unclear effects have an undetermined direction. A group can have separate benefits and burdens; these are counted separately.
Counts describe the number of identified effects, not their size or public value. Bill and clause counts are distinct within each view. Shared evidence may appear under several groups or policy areas, so their counts should not be added together.
Historical bill versions are included. Clauses analyzed in different versions count separately. A bill’s current status does not establish that every analyzed provision was enacted.
Only direct effects with high or medium confidence in the policy-area assignment are included. Bills are connected through sponsorship, cosponsorship, or Yea/Nay votes; a vote against a bill does not reverse its assessed effects. Vote dates filter recorded votes and vote-linked bills; sponsorship remains included.
